Salmen A - Search Results

1

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis.

Bagnoud M, Briner M, Remlinger J, Meli I, Schuetz S, Pistor M, Salmen A, Chan A, Hoepner R. Bagnoud M, et al. Among authors: salmen a. Cells. 2020 Sep 23;9(10):2154. doi: 10.3390/cells9102154. Cells. 2020. PMID: 32977663 Free PMC article.

2

Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Salmen A, Gold R, Chan A. Salmen A, et al. Clin Exp Immunol. 2014 May;176(2):135-48. doi: 10.1111/cei.12258. Clin Exp Immunol. 2014. PMID: 24358961 Free PMC article. Review.

3

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Hoepner R, Faissner S, Salmen A, Gold R, Chan A. Hoepner R, et al. Among authors: salmen a. J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049. eCollection 2014. J Cent Nerv Syst Dis. 2014. PMID: 24855407 Free PMC article. Review.

4

[New therapeutic options in multiple sclerosis].

Salmen A, Chan A. Salmen A, et al. Fortschr Neurol Psychiatr. 2015 Mar;83(3):174-86. doi: 10.1055/s-0034-1399247. Epub 2015 Mar 20. Fortschr Neurol Psychiatr. 2015. PMID: 25794324 Review. German.

5

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A. Schrewe L, et al. Among authors: salmen a. J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y. J Neuroinflammation. 2015. PMID: 26669675 Free PMC article.

6

Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.

Hoepner R, Kolb EM, Dahlhaus S, Hellwig K, Adams O, Kleiter I, Salmen A, Schneider R, Lukas C, Chan A, Berger JR, Gold R. Hoepner R, et al. Among authors: salmen a. Mult Scler. 2017 May;23(6):830-835. doi: 10.1177/1352458516667241. Epub 2016 Sep 6. Mult Scler. 2017. PMID: 27600113

7

Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis.

Kinner M, Hoepner R, Klotz P, Prehn C, Faissner S, Salmen A, Linker RA, Gold R, Chan A. Kinner M, et al. Among authors: salmen a. CNS Neurosci Ther. 2016 Dec;22(12):1019-1022. doi: 10.1111/cns.12652. Epub 2016 Oct 13. CNS Neurosci Ther. 2016. PMID: 27739247 Free PMC article. No abstract available.

8

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.

Salmen A, von Ahsen N, Trampe AK, Hoepner R, Plavina T, Subramanyam M, Kuesters G, Gold R, Chan A. Salmen A, et al. Mult Scler J Exp Transl Clin. 2016 Feb 8;2:2055217316630008. doi: 10.1177/2055217316630008. eCollection 2016 Jan-Dec. Mult Scler J Exp Transl Clin. 2016. PMID: 28607714 Free PMC article.

9

A Fully Automated Pipeline for Normative Atrophy in Patients with Neurodegenerative Disease.

Rummel C, Aschwanden F, McKinley R, Wagner F, Salmen A, Chan A, Wiest R. Rummel C, et al. Among authors: salmen a. Front Neurol. 2018 Jan 24;8:727. doi: 10.3389/fneur.2017.00727. eCollection 2017. Front Neurol. 2018. PMID: 29416523 Free PMC article.

10

Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.

Evangelopoulos ME, Miclea A, Schrewe L, Briner M, Salmen A, Engelhardt B, Huwiler A, Chan A, Hoepner R. Evangelopoulos ME, et al. Among authors: salmen a. CNS Neurosci Ther. 2018 Oct;24(10):984-986. doi: 10.1111/cns.12992. Epub 2018 Jun 13. CNS Neurosci Ther. 2018. PMID: 29898493 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page